A Phase 4 interventional study of Semaglutide 14 MG [Rybelsus] and Dapagliflozin (Forxiga) in Coronary Artery Disease and PreDiabetes, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Phase 4, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 4, and was the 17th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–75
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 97 across the 12 interventional studies, 336 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the anti-atherosclerotic efficacy of oral treatment with a GLP-1 analogue (semaglutide) or an SGLT-2 (so-called "flozin") inhibitor (dapagliflozin) versus routine treatment (metformin) in patients with pre-diabetes and diagnosed coronary artery disease at 24 months.
The diagnosis of coronary artery disease will be defined as the presence of coronary atherosclerosis confirmed by coronary artery computed tomography (coronary CT).
The study will evaluate the effect of treatment with flozin vs. semaglutide compared to treatment with metformin on the progression/regression of coronary atherosclerosis, change in plaque character, and control of cardiovascular risk factors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin + OMT \& Lifestyle Intervention
Drug: Dapagliflozin (Forxiga) · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention
Semaglutide + OMT \& Lifestyle Intervention
Drug: Semaglutide 14 MG [Rybelsus] · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention
Metformin + OMT \& Lifestyle Intervention
Drug: Metformin · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention
Semaglutide 3 mg daily - up-titrated to 7 mg daily if well tolerated - up-titrated to 14 mg daily if well tolerated
Dapagliflozin 10 mg daily
Metformin 500 mg daily (up-titrated to 1000 mg daily if indicated)
* cardiological counselling aiming to reduce risk factors of atherosclerosis progression (LDL target, optimal medical therapy, comorbidities management, electrocardiogram) in accordance with current European Society of Cardiology guidelines * dietary counselling * body weight management * advice on optimizing physical activity levels * advice on how to quit smoking if applicable * psychological counselling
Evaluation of the effect of GLP-1 analogue treatment on coronary artery disease progression AND Evaluation of the effect of flozin treatment on the progression of coronary artery disease (CO-PRIMARY ENDPOINTS)
Change in % volume of noncalcified atherosclerotic plaque in the coronary arteries assessed by coronary CT versus routine management (intention-to-treat) AND Change in % volume of noncalcified atherosclerotic plaque in the coronary arteries assessed by coronary CT versus routine management (intention-to-treat)
Time frame: 24 months
Evaluation of the effect of each of the tested drugs vs. control group on progression of coronary artery disease
% change in volume of noncalcified atherosclerotic plaque assessed by coronary CT (as treated) between baseline and end of study
Time frame: 24 months
Comparison of the effect of semaglutide vs. flozin on coronary artery disease progression
% change in volume of noncalcified atherosclerotic plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of the effect of each study drug vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease
% change in volume of the entire atherosclerotic plaque assessed by coronary CT) (intention to treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease
% change in volume of individual components of atherosclerotic plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease (plaque conversion)
Conversion of non-calcified plaque to calcified plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on CV risk expressed as the dynamics of high-risk features
Change in the number of high-risk atherosclerotic lesions defined as the presence of at least 2 high risk features among: * Spotty calcifications * Low attenuation plaques (low attenuation plaque, i.e. plaque density \<30 HU) * positive remodeling * napkin ring sign assessed by coronary TK (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on CV risk on pericoronary fat attenuation index
Change in the Pericoronary Fat Attenuation Index assessed by coronary TK (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body weight
Change in total body mass (expressed in kilograms) (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body mass index
Change in body mass index (BMI), calculated as following body mass index (BMI) = total body mass / (height)\^2 and expressed in kg/m2 (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - total body fat
Change in totabl body fat mass (expressed in kilograms) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body cell mass
Change in Body Cell Mass (BCM) (expressed in kilograms) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - fat to mass ratio
Change in fat to mass ratio (FMR), calculated as following fat to mass ratoi (FMR) = total body fat (TBF) / skeletal muscle mass measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - visceral fat area
Change in visceral fat area (expressed in cm2) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study
Time frame: 24 months
Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - waist-to-hip index
Change in waist-to-hip index (WHI) measured by bioimpedance analysis between baseline and end of study
Time frame: 24 months
Evaluation of change in inflammatory parameters in patients treated with semaglutide vs. patients treated with flozin
Change in concentration of high-sensitivity C-reactive protein between baseline and end of the study
Time frame: 24 months
Evaluation of change in lipid levels in patients treated with semaglutide vs. patients treated with flozin
Change in * total cholesterol * low-density lipoproteins (LDL) * high-density lipoproteins (HDL) * non-HDL cholesterol * triglycerides * lipoprotein A concentrations between baseline and end of the study
Time frame: 24 months
Evaluation of change in the percentage of glycated hemoglobin (HbA1c) in patients treated with semaglutide vs. patients treated with flozin
Change in the percentage of glycated hemoglobin (HbA1c) between baseline and end of study
Time frame: 24 months
Evaluation of change in the percentage of patients with normal blood pressure in patients treated with semaglutide vs. patients treated with flozin
Change in percentage of patients with normal blood pressure defined as systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg between baseline and end of study
Time frame: 24 months
Evaluation of change in the percentage of patients smoking tobacco or electronic cigarettes in patients treated with semaglutide vs. patients treated with flozin
Change in the percentage of patients smoking tobacco (cigarettes, pipe, cigar, tobacco heating products) or electronic cigarettes as defined by the study protocol between baseline and end of study
Time frame: 24 months
Evaluation of compliance with physical activity recommendations in patients treated with semaglutide vs. patients treated with flozin
Change in * Percentage of patients classified in the "high" physical activity category; * Percentage of patients classified in the "sufficient" physical activity category; * Percentage of patients classified in the "insufficient" physical activity category between baseline and end of study
Time frame: 24 months
Evaluation of dietary compliance in patients treated with semaglutide vs. patients treated with flozin
Change in the Dietary Approaches to Stop Hypertension (DASH) Index between baseline and end of study. For each of the 8 DASH food groups, a score of 10 is assigned when the DASH recommendation is met, lower intakes are scored proportionately, and the 8 individual scores are summed to create the overall DASH adherence score, which could range from 0 to 80. The higher the score, the better the adherence. Reference Günther AL, Liese AD, Bell RA, et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. Hypertension. 2009 Jan;53(1):6-12
Time frame: 24 months
Type 2 diabetes diagnosis
Number of patients diagnosed with of diabetes based on the criteria of the Polish Diabetes Association during the study
Time frame: 24 months
Evaluation of the onset of heart failure requiring hospitalization
Number of patients hospitalized for heart failure during the study
Time frame: 24 months
Number of unscheduled hospitalizations
Number of unscheduled hospitalizations during the study
Time frame: 24 months
Number of major cardiovascular events and strokes (MACCE: death/myocardial infarction/revascularization/stroke) separately and combined
Number of cardiovascular events and strokes (MACCE: death/myocardial infarction/revascularization/stroke) during the study
Time frame: 24 months
Homeostatic Model Change Assessment - Insulin Resistance (HOMA-IR)
Change in Homeostatic Model Assessment - Insulin Resistance (HOMA-IR) between baseline and of study
Time frame: 12 and 24 months
Evaluation of change in the concentration of selected oxidative stress markers - catalase
Change in plasma concentration of catalase between baseline and end of study
Time frame: 12 months and 24 months
Evaluation of change in the concentration of selected oxidative stress markers - superoxide dismutase (SOD)
Change in plasma concentration of superoxide dismutase (SOD) between baseline and end of study
Time frame: 12 months and 24 months
Evaluation of change in the concentration of selected oxidative stress markers - Oxygen Radical Absorbance Capacity (ORAC)
Change in concentration of Oxygen Radical Absorbance Capacity (ORAC) between baseline and end of study
Time frame: 12 months and 24 months
Evaluation of change in the concentration of selected oxidative stress markers - total antioxidant capacity (TAC)
Change in concentration of total antioxidant capacity (TAC) between baseline and end of study
Time frame: 12 months and 24 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Aug 2029, 48 months after the start.
Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Semaglutide · Dapagliflozin
National Institute of Cardiology, Warsaw, Poland